Escalating weekly doses of cetuximab: A phase I trial in advanced solid tumors

13012 Background: Cetuximab, an IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR), is FDA-approved at a 400 mg/m2 loading dose, followed by 250 mg/m2 weekly main...